Marketed New Drug Delivery Systems for Opioid Agonists/Antagonists ‎Administration: A Rapid Overview

Document Type : Review Article(s)


1 Pharmaceutics Research Center, Neuropharmacology Institute, Kerman University of ‎Medical Sciences, Kerman, Iran

2 ‎Professor, Pharmaceutics Research Center, Neuropharmacology Institute, Kerman ‎University of Medical Sciences, Kerman, Iran


Novel drug delivery systems for controlled-release of opioid agonists as a long time painkillers or opioid antagonists for opium, heroin, and alcohol addiction are under development or in clinical use today. In this article, the field of “new drug delivery systems” is momentarily reviewed from the viewpoint of the marketed opioid agonists/antagonists dosage forms today.


  1. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006; 58(14): 1456-9.
  2. Varshosaz J, Pardakhty A, Hajhashemi VI, Najafabadi AR. Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Deliv 2003; 10(4): 251-62.
  3. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012; 63: 185-98.
  4. Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012; 67(3): 715-22.
  5. Heiskanen T, Matzke S, Haakana S, Gergov M, Vuori E, Kalso E. Transdermal fentanyl in cachectic cancer patients. Pain 2009; 144(1-2): 218-22.
  6. Rektor I, Babic T, Boothmann B, Polivka J, Boroojerdi B, Randerath O. High doses of rotigotine transdermal patch: results of an open-label, dose- escalation trial in patients with advanced-stage, idiopathic Parkinson disease. Clin Neuropharmacol 2009; 32(4): 193-8.
  7. Youan BB. Chronopharmaceutical drug delivery systems: Hurdles, hype or hope? Adv Drug Deliv Rev 2010; 62(9-10): 898-903.
  8. Malaterre V ,Ogorka J, Loggia N, Gurny R. Approach to design push-pull osmotic pumps. Int J Pharm 2009; 376(1-2): 56-62.
  9. Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004; 28(7): 1051-9.
  10. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000; 35(6): 587-93.
  11. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001; 25(11): 1634-47.
  12. Johnson BA. Naltrexone long-acting formulation in the treatment of alcohol dependence. Ther Clin Risk Manag 2007; 3(5): 741-9.
  13. Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology (Berl) 2006; 189(1): 37-46.
  14. Comer SD, Sullivan MA, Hulse GK. Sustained- release naltrexone: novel treatment for opioid dependence. Expert Opin Investig Drugs 2007; 16(8): 1285-94.
  15. Krupitsky EM, Blokhina EA. Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry 2010; 23(3): 210-4.
  16. Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther 2005; 27(2): 225-37.
  17. Jumbelic MI. Deaths with transdermal fentanyl patches. Am J Forensic Med Pathol 2010; 31(1): 18-21.
  18. Zernikow B, Michel E, Anderson B. Transdermal fentanyl in childhood and adolescence: a comprehensive literature review. J Pain 2007; 8(3): 187-207.
  19. Edinboro LE, Poklis A, Trautman D, Lowry S, Backer R, Harvey CM. Fatal fentanyl intoxication following excessive transdermal application. J Forensic Sci 1997; 42(4): 741-3.
  20. Lilleng PK, Mehlum LI, Bachs L, Morild I. Deaths after intravenous misuse of transdermal fentanyl. J Forensic Sci 2004; 49(6): 1364-6.
  21. Jumbelic MI. Deaths with transdermal fentanyl patches. Am J Forensic Med Pathol 2010; 31(1): 18-21.
  22. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007; 5(7): 327-34.
  23. Borland M, Jacobs I, King B, O'Brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med 2007; 49(3): 335-40.
  24. Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine (Phila Pa 1976) 2005; 30(22): 2484-90.
  25. Ackerman SJ, Mordin M, Reblando J, Xu X, Schein J, Vallow S, et al. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm 2003; 9(3): 223-31.
  26. Hassenbusch SJ, Garber J, Buchser E, Du Pen S, Nitescu P. Alternative intrathecal agents for the treatment of pain. Neuromodulation 1999; 2(2): 85-91.
  27. Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm 2007; 328(2): 130-41.
  28. Nagle PC, Gerancher JC. DepoDur® (extended- release epidural morphine): A review of an old drug in a new vehicle. Techniques in Regional Anesthesia and Pain Management 2007; 11(1): 9-18.
  29. Howell SB. Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology. Cancer J 2001; 7(3): 219-27.
  30. Gambling D, Hughes T, Martin G, Horton W, Manvelian G. A comparison of Depodur, a novel, single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery. Anesth Analg 2005; 100(4): 1065-74.
  31. Carvalho B, Roland LM, Chu LF, Campitelli VA, Riley ET. Single-dose, extended-release epidural morphine (DepoDur) compared to conventional epidural morphine for post-cesarean pain. Anesth Analg 2007; 105(1): 176-83.
  32. Webster L .Update on abuse-resistant and abuse- deterrent approaches to opioid formulations. Pain Med 2009; 10(Suppl 2): S124-S133.
  33. Moorman-Li R, Motycka CA, Inge LD, Congdon JM, Hobson S, Pokropski B. A review of abuse-deterrent opioids for chronic nonmalignant pain. P T 2012; 37(7): 412-8.
  34. Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. J Pain 2010; 11(7): 602-11.
  35. Jang DH, Rohe JC, Hoffman RS, Nelson LS. Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda). Ann Emerg Med 2010; 55(3): 303-4.
  36. Bannwarth B. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Drugs 2012; 72(13): 1713-23.
  37. Katz N, Sun S, Johnson F, Stauffer J. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain 2010; 11(4): 303-11.
  38. Zhang WZ, Yu WJ, Zhao XL, He BX. Pharmacoeconomics evaluation of morphine, MS contin and oxycodone in the treatment of cancer pain. Asian Pac J Cancer Prev 2014; 15(20): 8797-800.
  39. Rauck RL, Bookbinder SA, Bunker TR, Alftine CD, Ghalie R, Negro-Vilar A, et al. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag 2006; 2(3): 155-66.
  40. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6(10): 662-72.
  41. Mastropietro DJ, Omidian H. Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm 2013; 39(5): 611-24.
  42. Hale ME, Ahdieh H, Ma T, Rauck R, Oxymorphone ER. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007; 8(2): 175-84.
  43. Panchagnula R, Bokalial R, Sharma P, Khandavilli S. Transdermal delivery of naloxone: skin permeation, pharmacokinetic, irritancy and stability studies. Int J Pharm 2005; 293(1-2): 213-23.
  44. Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT Jr, Dornseif BE, et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 2002; 23(5): 355-68.
  45. Wallace M, Skowronski R, Khanna S, Tudor IC, Thipphawong J. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127). Curr Med Res Opin 2007; 23(5): 981-9.
  46. Hale M, Tudor IC, Khanna S, Thipphawong J. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther 2007; 29(5): 874-88.
  47. Serpell M, Tripathi S, Scherzinger S, Rojas-Farreras S, Oksche A, Wilson M. Assessment of transdermal buprenorphine patches for the treatment of chronic pain in a UK observational study. Patient 2016; 9(1): 35-46.